
|Articles|July 18, 2016
Kelly Blackburn Appointed Bach Pharma CEO
July 18, 2016
Advertisement
Bach Pharma Inc. (North Andover, MA) has appointed Kelly Blackburn as Chief Executive Officer.
Ms. Blackburn was previously Vice President of Clinical Affairs at aTyr Pharma (San Diego, CA). Prior to that she was at Vertex Pharmaceuticals.
Ms. Blackburn is tasked with leading Bach Pharma as it brings its lead candidate, GVT, into the clinic.
The company also announced that Mark O. Henry will serve as Chief Financial Officer, transitioning from his role as CEO.
Newsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Bayer Shares Briefly Dip After Activist Investor Offloads Millions of Dollars in Company Stock
2
Pharmaceutical Executive Daily: FDA Issues Warning Letter to ImmunityBio
3
Pharma M&A Roundup: Merck to Acquire Terns Pharmaceuticals, Shionogi to Acquire 50% of Apnimed’s Ownership of Shionogi-Apnimed Sleep Science
4
FDA Sends Warning Letter to ImmunityBio for Misleading Claims in Advertisement
5




